
4-year-old Bakersfield girl facing deportation could die within days of losing medical care
The girl was a year delayed because she had spent most of her short life in a hospital in Playa del Carmen, Mexico, tethered to feeding tubes 24 hours a day. She has short bowel syndrome, a rare condition that prevents her body from completely absorbing the nutrients of regular food.
Vargas and her husband were desperate to get their daughter, whom The Times is identifying by her initials, S.G.V., better medical care. In 2023, they received temporary humanitarian permission to enter the U.S. legally through Tijuana.
Now in Bakersfield, the family received notice last month that their legal status had been terminated. The letter warned them: 'It is in your best interest to avoid deportation and leave the United States of your own accord.'
But doing so would put S.G.V., now a bubbly 4-year-old, at immediate risk of death.
'This is a textbook example of medical need,' said the family's attorney, Rebecca Brown, of the pro bono legal firm Public Counsel. 'This child will die and there's no sense for that to happen. It would just be a cruel sacrifice.'
A spokesperson for U.S. Citizenship and Immigration Services declined to comment.
Children's Hospital Los Angeles, where the girl regularly receives treatment, declined to comment. But in a letter requested by the family, Dr. John Arsenault of CHLA wrote that he sees the girl every six weeks.
If there is an interruption in her daily nutrition system, called Total Parenteral Nutrition (TPN), the doctor wrote, 'this could be fatal within a matter of days.'
'As such, patients on home TPN are not allowed to leave the country because the infrastructure to provide TPN or provide immediate intervention if there is a problem with IV access depends on our program's utilization of U.S.-based healthcare resources and does not transfer across borders,' Arsenault wrote.
Vargas, 28, is from the Mexican state of Oaxaca; her husband, 34, is from Colombia. They met in Cancun, where they were working. Just before S.G.V. was born, the couple moved to nearby Playa del Carmen so her husband could work as an Uber driver.
The girl was born a month premature and quickly taken to intensive care. After doctors discovered her condition, she underwent six surgeries to fix an intestinal blockage. But Vargas said the doctors cut out too much, and the girl was left with short bowels. She experienced repeated blood infections, including one that nearly killed her.
The girl's weight fluctuated severely. One month, she would look emaciated, her tiny limbs and bulging stomach incongruous with the family's relative access to resources. Another month, she was as round-cheeked as any other baby.
When S.G.V. was 7 months old, a doctor suggested that the family relocate to Mexico City, where pediatric care for short bowel syndrome was the best in the country. But although her condition initially improved, the blood infections continued.
Unable to work, Vargas spent all day, every day, at the hospital with her daughter. Some days, she said, nurses would mistakenly administer the wrong medication to S.G.V. Other days, Vargas would arrive to find that her daughter had thrown up on herself overnight and no one had cleaned her up.
Vargas tried to keep a watchful eye over her daughter. Even so, she said a nurse once mistakenly sped up S.G.V.'s nutrition system, causing her to quickly pee it out. The girl became dehydrated and her glucose levels skyrocketed before doctors whisked her to intensive care, where her condition stabilized.
Vargas had read about children similar to her daughter going on to have normal lives in other countries. In Mexico, her daughter was being kept alive — but at 2, her condition had not improved.
So when Vargas learned that the Biden administration had begun offering migrants appointments with border agents through a phone application called CBP One, she signed up. Those let in received two-year protection from deportation and work permits.
With the appointment set for July 31, 2023, Vargas and her family set out for Tijuana two days earlier. She carefully carried her daughter out of the hospital, her nutrition bags still connected intravenously.
Her husband told agents that he had once been kidnapped by cartel members in Mexico who extorted money and threatened to kill him. They also looked at the girl, whose vulnerable condition was obvious.
'God knew she needed better treatment,' Vargas said. 'When we got to the entrance, they saw her and asked us if we needed medical help.'
By that afternoon, the family had been whisked to Rady Children's Hospital-San Diego.
S.G.V. quickly improved. Although she once was hooked up 24 hours a day to the feeding system that delivered nutrients directly into the bloodstream, doctors began weaning her off as her intestines got stronger.
A year later, doctors referred her to Children's Hospital Los Angeles, which has one of the top-ranked gastroenterology programs in the country.
Both of her parents worked, holding down odd jobs, and by September 2024, the family had settled in Bakersfield and S.G.V. was discharged from the hospital.
For the first time, S.G.V. experienced the outside world. At Walmart, her eyes widened from the shopping cart and she and her mom strolled the aisles.
'It was incredible,' Vargas said. 'I had waited so long for doctors to tell me, 'Ma'am, your daughter is OK now. She can go home.''
Now, the girl spends 14 hours each night hooked up to the intravenous feeding system. She wears a backpack to take it on the go.
Four times a day, for an hour, her mom administers a different type of nutrition that goes straight into her stomach through a gastric tube. When the girl goes to preschool, she takes a larger backpack containing the milky fluid, and the school nurse administers her noon feeding.
Before S.G.V. takes a shower, Vargas unplugs her IV tubes, flushes them with saline and tapes a plastic sheet over her chest to keep water from getting in and infecting the area.
On a recent morning, Vargas dressed the girl in pink leggings, a Hello Kitty T-shirt and black Puma sneakers. As they left hand-in-hand for preschool, S.G.V.'s curly black hair was still wet and the adult-size backpack dangled behind her knees as she walked.
S.G.V.'s care is covered through Medi-Cal. But life in the U.S. isn't cheap.
Their modest living room contains little more than a hot plate on a folding table, a mini-fridge, a single chair and an IV bag stand. With no full kitchen, Vargas mostly makes sandwiches or soups. The fridge is filled with S.G.V.'s nutrition packs.
Vargas recently found steady work cleaning a restaurant. Finally, she thought, the family was achieving a sense of stability.
Then in April she received the notice from immigration authorities. This month, she received a notice terminating her employment authorization.
Vargas said she and her husband sometimes eat just once a day after paying rent and utilities, as well as for diapers and other necessities. Her husband is currently unemployed because of an injury, and she fears that losing her income could leave them homeless.
The thought of being forced by immigration agents to return to Mexico terrifies Vargas.
'I know the treatment they have there for her is not adequate, because we already lived it,' she said. 'Those were bad times. Here she is living the most normal life possible.'
If not for her daughter's medical condition, Vargas said, they probably would still be in Mexico. They want to stay only for as long as the girl needs treatment. Exactly how long that could be is unclear, but the couple are hopeful that their child's condition will improve enough that she stops requiring supplemental nutrition.
Brown, their lawyer, submitted a petition for a continuation of their temporary humanitarian legal status based on S.G.V.'s medical condition. She believes the family's legal status was prematurely terminated by mistake.
President Trump lambasted Biden over his broad expansion of programs allowing humanitarian entry, known as parole. On his first day in office, Trump issued an executive order to ensure that the discretionary authority be 'exercised on only a case-by-case basis' for urgent humanitarian reasons or a significant public benefit.
'This is the intended purpose — to help the most vulnerable who need attention here,' Brown said. 'We can avoid having harmed the child and the family.'
Although Trump said on the campaign trail that he would target criminals for deportation, his administration quickly began revoking the legal status of immigrants who have no criminal history.
The Trump administration has stripped humanitarian protections from hundreds of thousands of immigrants who entered the U.S. under various Biden-era programs. Thousands of people who similarly entered the country using the CBP One app received notices from the federal government around the same time Vargas did, ordering them to leave voluntarily or face criminal prosecution and other legal actions.
The same phone app that Vargas used to enter the country has since been turned into CBP Home, to help immigrants such as her self-deport. If not, it says, 'the federal government will find you.'
Times staff photographer Myung J. Chun in Bakersfield contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge
The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico's biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-private partnerships, further bolsters this growth. Emerging challenges include high setup costs and complex regulatory requirements, offering opportunities for innovation and collaboration. Mexican Microcarrier Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Mexico Microcarrier Market to Reach US$ 77.65 Million by 2033 - 7.66% CAGR Growth Driven by Biopharma Demand" report has been added to Mexico Microcarrier Market is expected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, with a CAGR of 7.66% from 2025 to 2033. Growing investment in regenerative medicine and cell therapy, growing demand for cell-based vaccines and biologics, technological advancements in culture efficiency, and expansion of biopharmaceutical research and development in Mexico. Mexico's growing biopharmaceutical and biotechnology industries depend heavily on the microcarrier industry. The large-scale manufacturing of biologics, vaccines, and cell treatments depends on microcarriers, which are tiny, spherical particles that promote the proliferation of adherent cells in bioreactors. As Mexico looks to improve its local manufacturing capabilities in response to growing healthcare demands and the need for medical product self-sufficiency, these applications become more and more market is expanding due to a number of causes. Research and development expenditures, along with the nation's strategic efforts to strengthen its biomanufacturing infrastructure, are essential. The need for effective cell culture systems is further fueled by the aging population and the rising incidence of chronic diseases, which increase demand for cutting-edge treatment solutions. Additionally, Mexico has easier access to cutting-edge biotechnologies, such as microcarrier-based cell culture systems, thanks to its involvement in international health programs and collaborations with foreign the encouraging growth trajectory, the Mexican microcarrier market still confronts obstacles including the requirement for specialized technological know-how and the development of strong regulatory frameworks to guarantee the quality and safety of the products. Nonetheless, these difficulties offer chances for creativity and cooperation. These problems can be resolved by creating training initiatives, establishing regulatory guidelines, and encouraging public-private partnerships. This will create an atmosphere that is favorable for the expansion of the microcarrier market and the larger biopharmaceutical sector in Factors Driving the Mexico Microcarrier Market Growth Increasing Demand for Cell Therapy and BiopharmaceuticalsMicrocarrier systems are in high demand due to Mexico's growing biopharmaceutical industry, which includes the manufacture of vaccines, biologics, and cell treatments. Businesses are depending more and more on microcarriers to sustain high density adherent cell cultures in bioreactors as local R&D becomes more intense and manufacturing capacity need is particularly noticeable in the creation of therapeutic proteins, monoclonal antibodies, and items related to regenerative medicine. Scalable and effective cell culture is made possible by microcarriers, which is necessary for the commercial production of biologics and sophisticated cell culture systems are now a vital enabling technology for Mexico's biomanufacturing efforts as the nation develops its capacities in these fields and aligns with international health Development and Manufacturing ExpansionMexico's bioprocessing infrastructure is being quickly strengthened through government sponsored initiatives and strategic public-private partnerships. The adoption of effective cell culture technologies is being fueled by investments in upstream bioprocessing facilities, automation, single use systems, and digital technology is also supported by the growth of industry academia partnership and regulatory modernization (e.g., COFEPRIS's digital transformation). These advancements promote easier technology transfer from research to production and improve the technical preparedness required for microcarrier is therefore better able to scale complex bioprocesses, which increases the accessibility of microcarriers for biotechnology companies, contract manufacturers, and academic institutions seeking to increase their capacity for and Technological Progress in MicrocarriersPerformance and scalability have been greatly enhanced by innovations in microcarrier design, such as surface functionalized beads, biodegradable materials, and compatibility with single use bioreactors. Manufacturers who prioritize quality and cost effectiveness are placing a greater value on enhanced features like increased yield, better cell adhesion, and lower contamination developments, when combined with automation, intelligent sensor integration, and digital process control, reduce human error and streamline production. Modern microcarrier formats are becoming feasible choices for biomanufacturers and researchers nation wide due to Mexico's rising alignment with international industry trends and the country's expanding adoption of state of the art bioprocessing in the Mexico Microcarrier Market Expensive Startup and Ongoing CostsMicrocarrier based cell culture system deployment requires a large financial outlay, especially for equipment such as bioreactors, single use systems, and associated infrastructure. Traditional planar culture techniques are still less expensive at lower scales because they require less like microcarrier beads make up a significant portion of the continuous expenses for microcarrier setups, which frequently require tens or even hundreds of thousands of dollars in capital expenditure. GMP grade, high quality microcarriers can account for 20-25% of total consumable financial barriers, in addition to media supplies and labor training, make the technology hard to adopt in Mexico, where a large number of biotech companies and academic institutions have tight budgets. Despite the long term productivity and efficiency benefits of microcarriers, this hinders scale of Regulations and Documentation NeedsUnder the General Health Law, COFEPRIS is in charge of regulating microcarrier based cell culture in Mexico, particularly when it is meant for clinical or therapeutic applications. In accordance with ICH guidelines, businesses are required to compile comprehensive Common Technical Document (CTD) dossiers that include clinical, non clinical, and quality is necessary to adhere to Official Mexican Standards (such as NOM?257?SSA1?2014, NOM?059?SSA1?2015), especially those that deal with GMP, bio comparability, and safety assessment. Microcarrier systems need to be thoroughly validated, which includes testing for batch uniformity, sterility, and cell material obstacles to commercialization include the burden of complicated documentation and testing, changing regulations, and unclear advanced therapeutic standards. Market access may be delayed, more expensive, and unclear for entities without local regulatory partnerships or past dossier experience. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Thermo Fisher Scientific Merck KGaA Eppendorf AG Danaher Corporation Sartorius AG Bio Rad Laboratories, Inc. Corning Inc. Lonza Group Getinge Becton, Dickinson and Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $39.96 Million Forecasted Market Value (USD) by 2033 $77.65 Million Compound Annual Growth Rate 7.6% Regions Covered Mexico Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Mexico Microcarrier Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Application6.3 By End User6.4 By Region7. Product Type7.1 Consumables7.1.1 Microcarrier Beads7.1.2 Media & Reagents7.2 Equipment8. Application8.1 Cell Therapy8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Vaccine Manufacturing8.3 Others9. End User9.1 Pharmaceutical & Biotechnology Companies9.2 Contract Research Organizations & Contract Manufacturing Organizations9.3 Academic & Research Institutes10. Region10.1 Northern Mexico10.2 Central Mexico10.3 Southern Mexico10.4 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Thermo Fisher Scientific14.2 Merck KGaA14.3 Eppendorf AG14.4 Danaher Corporation14.5 Sartorius AG14.6 Bio-Rad Laboratories, Inc.14.7 Corning Inc.14.8 Lonza Group14.9 Getinge14.10 Becton, Dickinson and Company15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Mexican Microcarrier Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


UPI
5 days ago
- UPI
Initial results show promise for Eli Lilly's new weight loss drug
A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks. Eli Lilly says it plans to apply for U.S. Food and Drug Administration approval by the end of the year to market the drug. If approved, the pill could become a simpler alternative to injectable medications like Wegovy, Ozempic, Zepbound and Mounjaro, which are used to treat obesity and type 2 diabetes. Pills are easier to make and "can be manufactured at a significant scale," Kenneth Custer, Eli Lilly's president of cardiometabolic health, told The New York Times. "There are orders of magnitude differences in how many we can support," he said, adding that pills could also help people in countries without access to cold storage needed for injected drugs. Like the injected medications, the new pill belongs to the GLP-1 class of drugs. GLP-1 drugs work by helping people feel full longer and by slowing digestion, according to the Cleveland Clinic. The recent study included 3,127 adults who were randomly assigned to take orforglipron or a placebo. Three different dosages of the drug were evaluated. In addition to weight loss, people taking the drug also saw improvements in cholesterol, triglyceride levels and blood pressure. Side effects were similar to those seen with injectable drugs and included vomiting, diarrhea, constipation and indigestion, The Times said. Earlier this year, Lilly also tested orforglipron in people with type 2 diabetes and found that it lowered blood sugar and led to weight loss similar to Ozempic. The company plans to seek FDA approval to market the drug for diabetes use in 2026, The Times reported. Orforglipron has not yet been compared directly with injected drugs like Wegovy or Zepbound. In a previous study, Zepbound helped people lose 20.2% of their weight, and Wegovy led to a 13.2% weight loss over 72 weeks. Still, experts say the new pill may have key benefits. It may not be as powerful as injections, though, said Dr. David Cummings, an obesity expert at the University of Washington in Seattle. But if it's a lot cheaper and easier to make, Cummings said, then "that feature alone could make it truly impactful." Eli Lilly has not yet said how much the pill will cost, and plans to decide after the FDA reviews it for marketing approval. About 8 million Americans now take obesity medications, even though an estimated 170 million could benefit, according to Custer. He said a major reason is that making injected drugs is expensive and slow, The Times said. Because pills are easier to make and store, this new drug could help reach more people, Custer added. More information Learn more about Eli Lilly's mission. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
5 days ago
- Yahoo
What to know about game-changing new weight-loss pill that could be prescribed on the NHS
Is it more or less effective than weight-loss jabs? A new study found the pill could help shed 12% of body weight. A daily pill that could help people lose a significant amount of weight – without injections – has shown promising early results in a major trial. The drug, called orforglipron, works in a similar way to known weight-loss jabs like Wegovy and Mounjaro, targeting hormones that regulate appetite and digestion. But instead of a weekly injection, it's taken daily in tablet form. In a study of more than 3,000 adults, those on the highest dose lost an average of 12.4% of their body weight over 72 weeks (almost 17 months) – that's nearly two stone for some. The trial also reported improvements in cholesterol, blood pressure and heart health, according to the study. Manufacturer Eli Lilly, the American pharmaceutical company which also created Mounjaro, says it plans to seek regulatory approval by the end of the year. Experts are cautiously optimistic, but stress the results are still preliminary and not yet peer reviewed. Here's what we know about the weight-loss pill so far. How does the weight-loss pill compare to injections? In head-to-head comparisons, injectables still lead on weight loss. Trials show Mounjaro users lose around 20% of their body weight, and Wegovy users about 13–14%. orforglipron's 12.4% average is slightly lower – but experts say its convenience could make it appealing. Kenneth Custer, the president of Eli Lilly, said: "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments." In the trial, nearly 60% of people on the top dose lost at least 10% of their body weight, and almost 40% lost 15% or more. What about side effects? The safety profile looks similar to other GLP-1 or weight-loss drugs, like Wegovy and Mounjaro. In the trial, the most common side effects – of which some participants reported more than one – were stomach-related: Nausea: 33.7% Constipation: 25.4% Diarrhoea: 23.1% Vomiting: 24.0% Indigestion: 14.1% Most side effects were mild to moderate, but they were enough to make some people stop treatment. Around one in 10 people on the top dose dropped out because of side effects, compared to about one in forty in the placebo group, those given a dummy pill with no active medicine. "These are preliminary, non-peer-reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken," Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University told The Times. "It should be noted that their effects on weight loss are not as profound as those seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10 per cent weight loss at the highest dose. "Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients," he added. Who could get the weight-loss pill on the NHS? If approved, orforglipron would likely be prescribed under similar rules to existing weight-loss drugs. Currently, Wegovy is offered to people with a BMI of at least 35 plus a weight-related condition, or a BMI of 30–34.9 if referred to specialist services. Mounjaro is approved for those with a BMI over 30, or 27–30 with health issues such as pre-diabetes or high blood pressure. Any rollout would almost certainly involve combining the pill with the recommended reduced-calorie diet and more physical activity, just like the current injections. How much will the weight-loss pills cost? There's no official price tag yet for orforglipron. Eli Lilly hasn't confirmed how much it will sell for if approved, but experts expect it to be cheaper to manufacture than injections like Wegovy or Mounjaro. That could mean a lower cost for the NHS, and potentially make it more accessible for patients if offered privately. Read more about weight loss: Who can get new weight-loss jab Mounjaro on the NHS? (Yahoo Life UK, 4-min read) Alison Hammond reveals why she is 'frightened' of weight loss medications (Yahoo Life UK, 3-min read) Obesity rates may start falling this year due to weight loss jabs, seller says (Sky News, 4-min read)